Insider · CIK 0001737613
Erin Lavelle
Files at AVLN (Avalyn Pharma Inc.), JBIO (Jade Biosciences, Inc.). First filing -, latest -.
Erin Lavelle files SEC Form 4 as director at AVLN (Avalyn Pharma Inc.), and also at JBIO (Jade Biosciences, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Erin Lavelle has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AVLN Avalyn Pharma Inc. | AGrant or award Stock Option (Right to Buy)derivative | +26,978 | $0.00 | $0 | 26,978 | May 1, 2026 |
| Apr 29, 2025 | JBIO Jade Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +23,017 | $0.00 | $0 | 23,017 | May 1, 2025 |
Questions about Erin Lavelle
Answered from the filings on this page, as of the latest one.
Is Erin Lavelle buying or selling?
Erin Lavelle has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Erin Lavelle's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Erin Lavelle has 0.
Where does Erin Lavelle file Form 4?
Erin Lavelle has filed Form 4 at AVLN (Avalyn Pharma Inc.); JBIO (Jade Biosciences, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.